Current reports
6-K
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
18 Apr 24
6-K
Current report (foreign)
18 Apr 24
6-K
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
16 Apr 24
6-K
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 Apr 24
6-K
Material Change Report
22 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Announces Oversubscribed Private Placement of U.S. $150 Million
20 Mar 24
6-K
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
18 Mar 24
6-K
Current report (foreign)
15 Mar 24
6-K
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
14 Mar 24
Registration and prospectus
D
$1.90 mm in options, 17 investors
22 Apr 24
SUPPL
Supplemental materials (foreign)
18 Apr 24
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
10 Apr 24
D
$108.70 mm in equity, sold $108.70 mm, 12 investors
3 Apr 24
F-X
Appointment of agent for service of process by issuers registering securities
29 Dec 23
F-10
Registration of securities (Canada)
29 Dec 23
D
$1.69 mm in options, 8 investors
29 Nov 23
SUPPL
Supplemental materials (foreign)
13 Nov 23
SUPPL
Supplemental materials (foreign)
23 Aug 23
SUPPL
Supplemental materials (foreign)
23 Aug 23
Proxies
No filings
Ownership
SC 13G
RA CAPITAL MANAGEMENT, L.P.
25 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
RANDS PETER DAVID
17 Nov 23
SC 13G
RANDS PETER DAVID
7 Nov 23
SC 13G
Point72 Asset Management, L.P.
15 Sep 23
SC 13G/A
ORBIMED CAPITAL LLC
14 Feb 23
SC 13G
ORBIMED CAPITAL LLC
11 Feb 22